Intranasal ketamine
Druglow dose
NCT Number: NCT00488787
Once patients' postoperative pain intensity reaches a moderate-to-severe level, they are randomized to receive intranasal ketamine or placebo. Patients remain in the study unit for 3 hours post administration and assess pain intensity and pain relief throughout the 3 hour postoperative period.
Looking for future studies?
Notify Me16 year and older
All sexes
Interventional
Phase 2
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
low dose
placebo
Time frame: 3 hours
Time frame: 3 hours
Javelin Pharmaceuticals
Industry
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of the Safety and Efficacy of 10 mg, 30 mg, and 50 mg of Transnasal Ketamine Hydrochloride (PMI-100) for the Treatment of Postoperative Dental Pain
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07165041
Agnosia, Nervous System Diseases
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT06282666
Acute Pain, Agnosia
Lublin, Poland
View Trial DetailsNCT04624880
Agnosia, Disease Attributes
Palo Alto, California, United States
View Trial DetailsNCT06217263
Agnosia, Chest Tubes
Istanbul, Turkey (Türkiye)
View Trial Details